One patient with GIST with a kit insertion received imatinib, and one patient with EMCS with an EWSR1-NR4A3 fusion received pazopanib, both in the course of standard clinical practice and regardless of NGS results. Here, NR4A3 is linked to gastrointestinal stromal tumor.